ACS and Melanoma Research Alliance to fund pilot research projects

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new partnership between the American Cancer Society and the Melanoma Research Alliance will fund research aimed at decreasing side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefits. FDA has approved use of checkpoint drugs to combat seven cancer types including lung, head and neck, kidney cancer, bladder cancer, Merkel...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login